Medicare access expands to a flat monthly co-pay
Eligible Part D beneficiaries gain a route that undercuts every compounded programme we track.
A federal programme agreed with manufacturers began dispensing on 1 July 2026, giving eligible Part D beneficiaries a flat monthly co-pay for covered weight-management products.
Compounded preparations are not included and are not covered by any public programme.
If you are Medicare-eligible and paying cash for compounded medication, this inverts the usual advice: an FDA-approved product at a flat public co-pay sits below every compounded route we price.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement or the clinical review behind a prescription.
Where a development moves a figure we publish, the change is recorded with its date on our methodology page rather than edited in silently.
How to verify this yourself
Regulatory claims should be checked against the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.